Nature Communications (Jun 2022)

Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials

  • Qianqian Xin,
  • Qianhui Wu,
  • Xinhua Chen,
  • Bihua Han,
  • Kai Chu,
  • Yan Song,
  • Hui Jin,
  • Panpan Chen,
  • Wanying Lu,
  • Tuantuan Yang,
  • Minjie Li,
  • Yuliang Zhao,
  • Hongxing Pan,
  • Hongjie Yu,
  • Lin Wang

DOI
https://doi.org/10.1038/s41467-022-30864-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 7

Abstract

Read online

Following a booster dose of CoronaVac in two single-centre phase 2 clinical trials, the authors show that neutralising antibody titres decline approximately 4-fold and 2.5-fold from day 28 to day 180 in adults aged 18-59 years and in adults aged 60 years and older, respectively.